Physician profile
Tomas Alejandro Moreno
NPI 1184967341
$4,231.71
in general payments reported to CMS, 2019-2025
14 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $118 · 2021: $457 · 2022: $772 · 2023: $1,960 · 2024: $282 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $1,663 · Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $1,662.90 |
| Food and Beverage | $999.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,421.33 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $733.52 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $218.78 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $207.09 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $155.53 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Coherus Oncology, INC. | $109.64 | 2022-2023 | |
| Abbvie INC. | $86.68 | 2022-2025 | |
| Astellas Pharma US INC | $81.02 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $75.15 | 2024 | Iheezo |
| Genentech USA, INC. | $63.78 | 2020-2022 | |
| Alimera Sciences, INC. | $58.23 | 2022-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $20.96 | 2025 | Xipere |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,187.10 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.